1. Home
  2. BZH vs PHAT Comparison

BZH vs PHAT Comparison

Compare BZH & PHAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • BZH
  • PHAT
  • Stock Information
  • Founded
  • BZH 1985
  • PHAT 2018
  • Country
  • BZH United States
  • PHAT United States
  • Employees
  • BZH N/A
  • PHAT N/A
  • Industry
  • BZH Homebuilding
  • PHAT Biotechnology: Pharmaceutical Preparations
  • Sector
  • BZH Consumer Discretionary
  • PHAT Health Care
  • Exchange
  • BZH Nasdaq
  • PHAT Nasdaq
  • Market Cap
  • BZH 666.1M
  • PHAT 640.9M
  • IPO Year
  • BZH 1994
  • PHAT 2019
  • Fundamental
  • Price
  • BZH $24.63
  • PHAT $9.63
  • Analyst Decision
  • BZH Strong Buy
  • PHAT Strong Buy
  • Analyst Count
  • BZH 3
  • PHAT 5
  • Target Price
  • BZH $33.00
  • PHAT $16.40
  • AVG Volume (30 Days)
  • BZH 336.1K
  • PHAT 1.1M
  • Earning Date
  • BZH 07-31-2025
  • PHAT 08-07-2025
  • Dividend Yield
  • BZH N/A
  • PHAT N/A
  • EPS Growth
  • BZH N/A
  • PHAT N/A
  • EPS
  • BZH 3.10
  • PHAT N/A
  • Revenue
  • BZH $2,436,131,000.00
  • PHAT $81,859,000.00
  • Revenue This Year
  • BZH N/A
  • PHAT $195.03
  • Revenue Next Year
  • BZH $15.69
  • PHAT $106.77
  • P/E Ratio
  • BZH $7.94
  • PHAT N/A
  • Revenue Growth
  • BZH 13.50
  • PHAT 3055.70
  • 52 Week Low
  • BZH $17.37
  • PHAT $2.21
  • 52 Week High
  • BZH $38.22
  • PHAT $19.71
  • Technical
  • Relative Strength Index (RSI)
  • BZH 58.74
  • PHAT 61.95
  • Support Level
  • BZH $23.01
  • PHAT $7.61
  • Resistance Level
  • BZH $25.91
  • PHAT $9.76
  • Average True Range (ATR)
  • BZH 0.89
  • PHAT 0.63
  • MACD
  • BZH 0.05
  • PHAT -0.07
  • Stochastic Oscillator
  • BZH 61.12
  • PHAT 93.95

About BZH Beazer Homes USA Inc.

Beazer Homes USA Inc is an construction company that focuses on residential construction. The company specializes in single-family housing and multi-unit building construction in over 13 states and over 22 metro markets. Beazer Homes builds homes and communities that target first-time, move-up, and luxury homebuyers with an average selling price of roughly $300,000. From a geographic perspective, home sales in the western and eastern United States have been the leading sources of revenue for the company. Key metro areas include Atlanta, Las Vegas, Los Angeles, Orlando, and Tampa. The company also focuses on land purchasing and development to support future construction efforts as well as mortgage services for its homebuyers.

About PHAT Phathom Pharmaceuticals Inc.

Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.

Share on Social Networks: